Reply to M. Horiguchi et al

J Clin Oncol. 2018 Mar 10;36(8):826-827. doi: 10.1200/JCO.2017.76.3748. Epub 2018 Jan 26.

Authors

Mario A Eisenberger¹, Wenping Zhang¹, Zhenming Shun¹, Johann de Bono¹

Affiliation

¹ Mario A. Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wenping Zhang, Sanofi, Bridgewater, NJ; Zhenming Shun, Sanofi, Cambridge, MA; and Johann de Bono, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom.

PMID: 29373098
DOI: 10.1200/JCO.2017.76.3748

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Male
Neoplasms, Second Primary*
Prostatic Neoplasms, Castration-Resistant*
Taxoids

Substances

Taxoids
cabazitaxel